Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark M Pomerantz, M.D.

Co-Author

This page shows the publications co-authored by Mark Pomerantz and Matthew Freedman.
Connection Strength

9.268
  1. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020 08; 52(8):790-799.
    View in: PubMed
    Score: 0.885
  2. The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer. Cancer. 2017 Sep 15; 123(18):3532-3539.
    View in: PubMed
    Score: 0.714
  3. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nat Genet. 2015 Nov; 47(11):1346-51.
    View in: PubMed
    Score: 0.636
  4. Clinical uncertainty of prostate cancer genetic risk panels. Sci Transl Med. 2013 Apr 24; 5(182):182ed6.
    View in: PubMed
    Score: 0.536
  5. The genetics of cancer risk. Cancer J. 2011 Nov-Dec; 17(6):416-22.
    View in: PubMed
    Score: 0.484
  6. Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila). 2011 May; 4(5):719-28.
    View in: PubMed
    Score: 0.462
  7. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
    View in: PubMed
    Score: 0.452
  8. Genetics of prostate cancer risk. Mt Sinai J Med. 2010 Nov-Dec; 77(6):643-54.
    View in: PubMed
    Score: 0.451
  9. The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet. 2009 Aug; 41(8):882-4.
    View in: PubMed
    Score: 0.411
  10. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res. 2009 Jul 01; 69(13):5568-74.
    View in: PubMed
    Score: 0.411
  11. Quantitative gene expression at the 8q24 prostate cancer risk locus. J Clin Oncol. 2008 May 20; 26(15_suppl):5055.
    View in: PubMed
    Score: 0.381
  12. Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis. Clin Cancer Res. 2022 Mar 01; 28(5):928-938.
    View in: PubMed
    Score: 0.247
  13. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nat Commun. 2021 03 30; 12(1):1979.
    View in: PubMed
    Score: 0.232
  14. Author Correction: Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 Oct; 26(10):1663.
    View in: PubMed
    Score: 0.224
  15. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020 07; 26(7):1041-1043.
    View in: PubMed
    Score: 0.220
  16. A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018 07 12; 174(2):422-432.e13.
    View in: PubMed
    Score: 0.191
  17. CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants. Nat Med. 2015 Nov; 21(11):1357-63.
    View in: PubMed
    Score: 0.158
  18. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A. 2012 Jul 10; 109(28):11252-7.
    View in: PubMed
    Score: 0.126
  19. Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev. 2010 Jul; 19(7):1871-8.
    View in: PubMed
    Score: 0.110
  20. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A. 2010 May 25; 107(21):9742-6.
    View in: PubMed
    Score: 0.109
  21. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res. 2009 May 01; 15(9):3223-30.
    View in: PubMed
    Score: 0.101
  22. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2008 Feb 20; 26(6):842-7.
    View in: PubMed
    Score: 0.094
  23. Genetic determinants of prostate cancer risk. BJU Int. 2007 Aug; 100(2):241-3.
    View in: PubMed
    Score: 0.089
  24. Androgen receptor and MYC equilibration centralizes on developmental super-enhancer. Nat Commun. 2021 12 15; 12(1):7308.
    View in: PubMed
    Score: 0.061
  25. Allele-specific epigenetic activity in prostate cancer and normal prostate tissue implicates prostate cancer risk mechanisms. Am J Hum Genet. 2021 11 04; 108(11):2071-2085.
    View in: PubMed
    Score: 0.060
  26. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nat Commun. 2021 10 01; 12(1):5775.
    View in: PubMed
    Score: 0.060
  27. A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate. 2021 07; 81(10):683-693.
    View in: PubMed
    Score: 0.058
  28. Trans-ethnic variation in germline variants of patients with renal cell carcinoma. Cell Rep. 2021 03 30; 34(13):108926.
    View in: PubMed
    Score: 0.058
  29. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat Cancer. 2021 Apr; 2(4):444-456.
    View in: PubMed
    Score: 0.058
  30. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021 02 05; 12(1):808.
    View in: PubMed
    Score: 0.057
  31. Correction: Evaluation of significant genome-wide association studies risk-SNPs in young breast cancer patients. PLoS One. 2020; 15(3):e0230529.
    View in: PubMed
    Score: 0.054
  32. Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations. Clin Cancer Res. 2020 06 01; 26(11):2673-2680.
    View in: PubMed
    Score: 0.054
  33. Allele-Specific QTL Fine Mapping with PLASMA. Am J Hum Genet. 2020 02 06; 106(2):170-187.
    View in: PubMed
    Score: 0.054
  34. Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Res. 2020 02 01; 80(3):624-638.
    View in: PubMed
    Score: 0.053
  35. Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nat Med. 2019 10; 25(10):1615-1626.
    View in: PubMed
    Score: 0.052
  36. CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation. Cancer Discov. 2019 11; 9(11):1538-1555.
    View in: PubMed
    Score: 0.052
  37. Sex specific associations in genome wide association analysis of renal cell carcinoma. Eur J Hum Genet. 2019 10; 27(10):1589-1598.
    View in: PubMed
    Score: 0.051
  38. Evaluation of significant genome-wide association studies risk - SNPs in young breast cancer patients. PLoS One. 2019; 14(5):e0216997.
    View in: PubMed
    Score: 0.051
  39. A Novel Mechanism Driving Poor-Prognosis Prostate Cancer: Overexpression of the DNA Repair Gene, Ribonucleotide Reductase Small Subunit M2 (RRM2). Clin Cancer Res. 2019 07 15; 25(14):4480-4492.
    View in: PubMed
    Score: 0.051
  40. The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study. PLoS Med. 2019 01; 16(1):e1002724.
    View in: PubMed
    Score: 0.050
  41. Corrigendum re "Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma" [Eur Urol 2017;72:747-54]. Eur Urol. 2018 09; 74(3):e85-e86.
    View in: PubMed
    Score: 0.048
  42. Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. Eur Urol. 2017 11; 72(5):747-754.
    View in: PubMed
    Score: 0.045
  43. Genome-wide association study identifies multiple risk loci for renal cell carcinoma. Nat Commun. 2017 06 09; 8:15724.
    View in: PubMed
    Score: 0.045
  44. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. Nat Genet. 2016 10; 48(10):1142-50.
    View in: PubMed
    Score: 0.042
  45. Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. Eur Urol Focus. 2016 Dec 15; 2(6):633-639.
    View in: PubMed
    Score: 0.041
  46. Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nat Commun. 2016 Apr 07; 7:10979.
    View in: PubMed
    Score: 0.041
  47. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. Cancer. 2016 Feb 01; 122(3):402-10.
    View in: PubMed
    Score: 0.040
  48. Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum Mol Genet. 2015 Oct 01; 24(19):5603-18.
    View in: PubMed
    Score: 0.039
  49. Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases. Hum Genet. 2015 Apr; 134(4):439-50.
    View in: PubMed
    Score: 0.038
  50. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol. 2013 Jan; 14(1):81-7.
    View in: PubMed
    Score: 0.033
  51. The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila). 2011 Dec; 4(12):2044-50.
    View in: PubMed
    Score: 0.030
  52. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20; 29(18):2565-73.
    View in: PubMed
    Score: 0.029
  53. Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):4506.
    View in: PubMed
    Score: 0.029
  54. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res. 2011 Mar 15; 17(6):1546-52.
    View in: PubMed
    Score: 0.028
  55. Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res. 2010 Nov 01; 16(21):5244-51.
    View in: PubMed
    Score: 0.028
  56. Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy. Cancer Epidemiol Biomarkers Prev. 2010 Jan; 19(1):1-8.
    View in: PubMed
    Score: 0.027
  57. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009 Aug; 5(8):e1000597.
    View in: PubMed
    Score: 0.026
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.